Particulars (in Rs. Cr) | Q3FY25 | Q3FY24 | YoY (%) | Q2FY25 | QoQ (%) |
---|---|---|---|---|---|
Revenue from Operations | 175.00 | 158.00 | 10.00% | 186.00 | -6.00% |
EBITDA | 45.00 | 37.00 | 21.00% | 49.00 | -9.00% |
EBITDA Margin (%) | 25.81% | 23.62% | 221 bps | 26.51% | (68) bps |
PAT | 19.00 | 13.00 | 50.00% | 20.00 | -1.00% |
EPS (Rs.) | 6.00 | 4.00 | 48.00% | 4.00 | 48.00% |
Source: Company Filings; stockaxis Research
Q3FY25 Result Highlights
Krsnaa Diagnostics delivered an in-line set of numbers for the quarter ended Q3FY25.
Consolidated net sales rose 10% to Rs.174.5 cr as compared to Rs.158 cr registered
in the same quarter of the preceding fiscal. Consolidated EBITDA saw a robust growth
of 21% YoY to Rs.45 cr while the EBITDA margin improved 221 bps YoY to 27%. This
improvement was driven by: (1) operating leverage from new centers; and (2) business
restructuring - business consultant services in-house (vs. outsourced earlier).
PAT jumped 50% YoY to Rs.19.4 cr aided by healthy topline growth and robust operational
performance.
Operational Highlights
Key Conference Call Takeaways
Guidance: (i) The management remains firm on its 25% revenue growth guidance with a sustainable EBITDAM of ~25%. (ii) Current ROCE is 10-12%, with improvement expected through an asset-light model, B2C expansion, and efficiency.
Key Developments During the Quarter
Receivable Days
Entry into Retail Diagnostics
Testing Infrastructure
Apulki Healthcare Partnership
Return on Capital
Ongoing Capex
Krsnaa Diagnostics delivered steady earnings in Q3FY25. The company has received the signed agreement from the Medical Superintendent, Sadar Hospital, Ranchi, Jharkhand for the commission, install, operate, and maintain the Radiology services (CT and MRI) on a public-private partnership basis at Sadar Hospital, Purulia Road, Ranchi. Also, the company has received the signed agreement from the Ranchi Institute of Neuropsychiatry & Allied Services (RINPAS), for the supply, installation, commission, operation, and maintain the Radiology Centre (CT&MRI) and pathology laboratory services on a PPP basis. Apart from the above-mentioned tenders, Krsnaa has a pipeline to execute 52 radiology centres and 1600 pathology centers. All these tenders are between 5-12 years in duration, thus providing long-term revenue visibility for the company. Management is confident of achieving topline growth of 25-30% in FY25 and an EBITDA Margin of 25-26%.
The company has strengthened its position in the oncology and cardiac diagnostics space by securing an exclusive 30+ year partnership with Apulki’s cancer and cardiac hospitals. We expect this partnership to be a big revenue driver in the medium to long term. Krsnaa is also looking to scale up its presence in the B2C segment, which will have differential pricing but will still be competitive compared to market rates. This will help improve margins and lead to a better working capital cycle. KRSNAA has also started to strengthen its B2B initiative, wherein itservices hospitals, nursing homes, and laboratories. They are presently serving more than 400 B2B labs, hospitals, and nursing homes and intend to expand to 1,000 in FY26. These initiatives will leverage the infrastructure laid out for B2G contracts and hence we expect to see meaningful leverage emerging from the business going forward.
Given the leading position of KDL as a diagnostics service provider, a strong revenue growth outlook is to be driven by ongoing capex and scope for profit margin expansion. At a CMP of Rs.709, the stock is trading at 19.4x FY26E. We recommend a HOLD rating on the stock.
Particulars (in Rs. Cr) | Q3FY25 | Q3FY24 | YoY (%) | Q2FY25 | QoQ (%) |
---|---|---|---|---|---|
Revenue from Operations | 175.00 | 158.00 | 10.00% | 186.00 | -6.00% |
Cost of Goods Sold | 40.00 | 34.00 | 16.00% | 45.00 | -11.00% |
Gross Profit | 135.00 | 124.00 | 9.00% | 141.00 | -5.00% |
Gross Profit Margin (%) | 77.14% | 78.30% | (116) bps | 75.90% | 124 bps |
Employee Benefit Expenses | 36.00 | 30.00 | 21.00% | 35.00 | 2.00% |
Fees to Hospitals and Others | 14.00 | 18.00 | -26.00% | 17.00 | -22.00% |
Other Expenses | 40.00 | 39.00 | 4.00% | 40.00 | 1.00% |
EBITDA | 45.00 | 37.00 | 21.00% | 49.00 | -9.00% |
EBITDA Margin (%) | 25.81% | 23.62% | 221 bps | 26.51% | (68) bps |
Depreciation | 23.00 | 21.00 | 7.00% | 22.00 | 2.00% |
EBIT | 22.00 | 16.00 | 38.00% | 27.00 | -18.00% |
Finance Cost | 6.00 | 4.00 | 48.00% | 6.00 | -4.00% |
Other Income | 9.00 | 4.00 | 127.00% | 5.00 | 101.00% |
Profit Before Tax | 26.00 | 16.00 | 58.00% | 25.00 | 0.00% |
Taxes | 6.00 | 3.00 | 94.00% | 6.00 | 4.00% |
PAT | 19.00 | 13.00 | 50.00% | 20.00 | -1.00% |
EPS (Rs.) | 6.00 | 4.00 | 48.00% | 4.00 | 48.00% |